 |
|
Combining therapies can improve survival for early-stage breast cancer patients
April 04, 2007Patients with early-stage breast cancer who are treated with both chemotherapy and tamoxifen have a higher survival rate than patients who receive only tamoxifen. But a combination of tamoxifen and ovarian suppression—treatment to stop the ovaries from functioning—did not show any additional benefits, according to two randomized clinical trials published in the April 4 Journal of the National Cancer Institute.
Survival rates improve for patients with early-stage breast cancer who receive a single method of treatment—either tamoxifen, ovarian suppression, or chemotherapy. Two international studies by the Adjuvant Breast Cancer Trials Collaborative Group were designed to test whether combining these treatments would provide additional benefits.
Judith Bliss of The Institute of Cancer Research in Sutton, England, and colleagues conducted two randomized controlled phase III clinical trials of 3,854 women with early-stage breast cancer, all of whom were treated with tamoxifen for five years. In the first trial, nearly half of the 2,144 premenopausal women were randomly assigned to receive ovarian suppression, and the other half did not. Some also received chemotherapy. In the second trial, 1,991 patients were randomly assigned to receive chemotherapy, and the other half were not. Some premenopausal women also had ovarian suppression.
The researchers found that chemotherapy treatment resulted in a modest yet sustained improvement in both relapse-free and overall survival. These improvements were especially strong in women younger than 50 years and in premenopausal women who did not receive ovarian suppression.
They also found that neither relapse-free survival nor overall survival was affected by the addition of ovarian suppression. However, the results indicate a possible benefit of ovarian suppression when given along side tamoxifen for a small group of women younger than 40 years who have ER-positive tumors (tumors that need estrogen to grow), especially when they are not receiving chemotherapy. The researchers called for further research into this group of breast cancer patients.
"Relapse-free survival benefits emerged early and were maintained, whereas overall survival benefits did not emerge for at least 5 years, reinforcing the need for long-term follow-up in chemotherapy trials," the authors write. The trials add "to the limited data available on the effects of combining long-term tamoxifen, chemotherapy, and ovarian ablation of suppression."
In an accompanying editorial, Kathleen Pritchard, M.D., of Toronto Sunnybrook Regional Cancer Centre, describes how the trial could have found more interesting results if there had been more data on patients' ER status. "Most of all, however, these studies stress the importance of establishing processes to ensure the availability of archived tumor specimens for all randomized adjuvant trials. The era in which such large important trials should be carried out without the archived correlational tumor samples is over."
Journal of the National Cancer Institute
The researchers found that chemotherapy treatment resulted in a modest yet sustained improvement in both relapse-free and overall survival. These improvements were especially strong in women younger than 50 years and in premenopausal women who did not receive ovarian suppression.
They also found that neither relapse-free survival nor overall survival was affected by the addition of ovarian suppression. However, the results indicate a possible benefit of ovarian suppression when given along side tamoxifen for a small group of women younger than 40 years who have ER-positive tumors (tumors that need estrogen to grow), especially when they are not receiving chemotherapy. The researchers called for further research into this group of breast cancer patients.
"Relapse-free survival benefits emerged early and were maintained, whereas overall survival benefits did not emerge for at least 5 years, reinforcing the need for long-term follow-up in chemotherapy trials," the authors write. The trials add "to the limited data available on the effects of combining long-term tamoxifen, chemotherapy, and ovarian ablation of suppression."
In an accompanying editorial, Kathleen Pritchard, M.D., of Toronto Sunnybrook Regional Cancer Centre, describes how the trial could have found more interesting results if there had been more data on patients' ER status. "Most of all, however, these studies stress the importance of establishing processes to ensure the availability of archived tumor specimens for all randomized adjuvant trials. The era in which such large important trials should be carried out without the archived correlational tumor samples is over."
Journal of the National Cancer Institute
Tamoxifen Current Events and Tamoxifen News RSSHunting for the Prozac Gene
Prozac works wonders for some depressed people, but not for others. In some cases, patients derive little benefit and at worst, it can lead to bizarre hallucinations and fits of rage.
Research needed to learn which DCIS patients may be candidates for less invasive therapy
Ductal carcinoma in situ (DCIS), the most common non-invasive lesion of the breast, presents unique challenges for patients and providers largely because the natural course of the untreated disease is not well understood.
Study of adjuvant endocrine treatment for breast cancer reveals cost of noncompliance
The largest study in the world of treatments for post menopausal, hormone positive breast cancer has shown that patients who continue to take exemestane or tamoxifen do significantly better than patients who start to take one or other drug (or tamoxifen followed exemestane) but then stop.
Medications Effective in Reducing Risks for Breast Cancer Can Also Cause Serious Side Effects
Three drugs that reduce a woman's chance of getting breast cancer also have been shown to cause adverse effects, according to a new report from the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health & Human Services.
Long-term tamoxifen use increases risk of an aggressive, hard to treat type of second breast cancer
While long-term tamoxifen use among breast cancer survivors decreases their risk of developing the most common, less aggressive type of second breast cancer, such use is associated with a more than four-fold increased risk of a more aggressive, difficult-to-treat type of cancer in the breast opposite, or contralateral, to the initial tumor.
Estrogen-Dependent Switch Tempers Killing Activity of Immune Cells
The sex hormone estrogen tempers the killing activity of a specific group of immune cells, the cytotoxic T cells (CTLs), which are known to attack tumor cells and cells infected by viruses.
Breast cancer drug shows promise against serious infections
An FDA-approved drug used for preventing recurrence of breast cancer shows promise in fighting life-threatening fungal infections common in immune-compromised patients, such as infants born prematurely and patients with cancer.
DACH1 a key protein for tumor suppression in ER+ breast cancer
Researchers from the Kimmel Cancer Center at Jefferson have identified a protein relationship that may be an ideal treatment target for ER+ breast cancer.
Study identifies how tamoxifen stimulates uterine cell growth and cancer
UCSF researchers have identified a new "feed-forward" pathway linking estrogen receptors in the membrane of the uterus to a process that increases local estrogen levels and promotes cell growth.
Newly appreciated membrane estrogen receptor important therapeutic target for breast cancer
New research at Rhode Island Hospital has uncovered the biological effects of a novel membrane estrogen receptor, a finding that has potential implications for hormonal therapy for breast cancer.
More Tamoxifen Current Events and Tamoxifen News Articles
 |
Tamoxifen and Breast Cancer (Yale Fastback Series) by Dr. Michael W. DeGregorio (Author), Valerie J. Wiebe (Author) This authoritative and timely book presents a balanced and accessible discussion of the diagnosis of breast cancer and the risks, benefits, and limitations of treatment alternatives, particularly tamoxifen. For this revised edition, the authors have added new information regarding the latest developments in the use of tamoxifen, especially the results of the Breast Cancer Prevention Trial. Other current issues discussed are raloxifene in chemoprevention, the use of hormone replacement therapy in breast cancer, new biologic agents, and other prevention strategies. |
|
Tamoxifen Side Effect: Changes in Uterine Lining.(Brief Article)(Statistical Data Included): An article from: Family Practice News by Guang-shing Cheng (Author) This digital document is an article from Family Practice News, published by International Medical News Group on February 1, 2000. The length of the article is 989 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Tamoxifen Side Effect: Changes in Uterine Lining.(Brief Article)(Statistical Data Included) Author: Guang-shing Cheng Publication: Family Practice News (Magazine/Journal) Date: February 1, 2000 Publisher: International Medical News Group Volume: 10 Issue: 3 Page: 18 Article Type: Brief Article, Statistical Data Included Distributed by... | |
 |
My Journey with Breast Cancer by Jo Ann Klein, MS, RN My journey with breast cancer from diagnosis to treatment to every day living. Must reading for the newly diagnosed.Kindle blogs are fully downloaded onto your Kindle so you can read them even when you're not wirelessly connected. And unlike RSS readers which often only provide headlines, blogs on Kindle give you full text content and images, and are updated wirelessly throughout the day. |
 |
Tamoxifen Citrate Crystals Polarized Microscopy Photographic Poster Print, 16x12 by Art.com Art.com is the world's largest retailer of art prints, posters, photographs, and framed artwork. With our huge selection of over 400,000 prints, you'll easily find the perfect piece for your home, office, or classroom. Our art is printed on quality paper. When you order framed artwork, the piece is built by our team of in-house professionals. Visit our Amazon store today at www.amazon.com/artdotcom to find Special Offers and search for products based on 'Artist Name' and 'Subject Categories' such as Movie, Music, Vintage, TV, Children, Travel, Kitchen, Museum Art, Animals, Floral, Motivational, and Sports. Art.com is dedicated to providing you with high quality products and service by offering you 100% satisfaction guaranteed. We ship internationally to over 80 countries. Decorate your... |
 |
New Treatments for Breast Cancer Breast cancer is becoming a greater threat to women's health, but there are new treatments emerging that will help women with the battle, including tumor vaccines and therapies which enhance immune response to cancer. This program focuses on the newest treatments emerging from research and for which patients they will be most appropriate. Ellie Guardino, M.D., PhD., is an Instructor in the Department of Medical Oncology at Stanford University School of Medicine. Dr. Guardino earned her MD/PhD in Microbiology and Immunology from Georgetown University. Following her residency in Internal Medicine at Harvard, she completed a fellowship in the Department of Medicine, Division of Oncology, at Stanford. Dr. Guardino is developing immune therapies and vaccines for breast cancer including... |
|
Tamoxifen's breast cancer benefits called into question.: An article from: Family Practice News by Kate Johnson (Author) This digital document is an article from Family Practice News, published by Thomson Gale on August 15, 2006. The length of the article is 638 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Tamoxifen's breast cancer benefits called into question. Author: Kate Johnson Publication: Family Practice News (Magazine/Journal) Date: August 15, 2006 Publisher: Thomson Gale Volume: 36 Issue: 16 Page: 8(1) Distributed by Thomson... | |
|
|
Tamoxifen Citrate Crystals Polarized Microscopy Photographic Poster Print, 32x24 by AllPosters.com AllPosters.com is the world's #1 seller of posters, prints, photographs, specialty products and framed art. We're dedicated to bringing our customers the best selection of high quality wall décor that is perfect for their home or office. Browse our catalog of over 300,000 items that include entertainment and specialty posters, decorative prints, and art reproductions. Whether you're looking for your favorite movie or music poster, a framed Monet reproduction, or a print of the Eiffel Tower you will find it at AllPosters.com. Visit our Amazon store today at www.amazon.com/allposters to find Special Offers and search by subject category or artist. AllPosters.com provides unmatched service with a 100% satisfaction guarantee. We ship internationally to over 80 countries. Decorate your... |
 |
Tamoxifen: Beyond the Antiestrogen by John A. Kellen (Author) Pharmacological research on the mechanisms and effects of tamoxifen. Purports to collate various and seemingly unrelated areas of research. Tamoxifen as a preventive agent is not covered. 27 contributors, 5 U.S. |
|
Long-Term Tamoxifen Treatment by V. Craig Jordan (Author) During the past 20 years taxomifen has become the most widely prescribed and most successful drug used in the treatment of breast cancer. In this volume, editor V. Craig Jordan provides articles that trace the development, pharmacology and clinical research surrounding this drug which, by the year 2000, could be used to treat as many as one million women annually. Drawing from research conducted by specialists in the US, the UK and Italy, the series of articles describes the clinical testing of tamoxifen, highlighting the benefits. Studies show that tamoxifen lowers cholesterol and can potentially protect women against osteoporosis and fatal coronary heart disease. Equally important is a discussion of side effects and possible drug interactions and how these issues relate to patient... | |
|
|
Tamoxifen Citrate Crystals Polarized Microscopy Photographic Poster Print, 40x30 by Art.com Art.com is the world's largest retailer of art prints, posters, photographs, and framed artwork. With our huge selection of over 400,000 prints, you'll easily find the perfect piece for your home, office, or classroom. Our art is printed on quality paper. When you order framed artwork, the piece is built by our team of in-house professionals. Visit our Amazon store today at www.amazon.com/artdotcom to find Special Offers and search for products based on 'Artist Name' and 'Subject Categories' such as Movie, Music, Vintage, TV, Children, Travel, Kitchen, Museum Art, Animals, Floral, Motivational, and Sports. Art.com is dedicated to providing you with high quality products and service by offering you 100% satisfaction guaranteed. We ship internationally to over 80 countries. Decorate your... |
| © 2009 BrightSurf.com |